

25 June 2026, Thursday



58th EPC/IAP joint meeting



Acibadem University Istanbul | TURKIYE
JUNE 24th-27th | 2026

25 June 2026, Thursday														
	BOSPHORUS HALL	TOPKAPI HALL	GALATA HALL	TAKSİM HALL	KADIKÖY HALL	A1 ROOM	A2 ROOM	A3 ROOM	SULTANS ROOM	BEBEK POSTER HALL	MODA POSTER HALL	BESİKTAŞ POSTER HALL		
07:00-08:00									EPC - Council Meeting				07:00-08:00	
08:00-08:30														08:00-08:30
08:30-08:55	Opening Ceremony													08:30-08:55
08:55-10:15	Hot Topics in Pancreatology & IAP Lifetime Achievement Award			STELLACU - CONSORTIUM									08:55-10:15	
10:15-10:45	Satellite Symposium	COFFEE BREAK & SPONSORS EXHIBITION					MEPAC Investigators' Meeting						10:15-10:45	
10:45-12:00	Pancreatic Cancer - Update 2026	Best Abstracts - Acute Pancreatitis	Best Abstracts Variat-I	STELLACU - CONSORTIUM									10:45-12:00	
12:00-13:00	Satellite Symposium												12:00-13:00	
13:00-14:00	LUNCH BREAK & POSTER ROUNDS & SPONSORS EXHIBITION				SBPC Meeting	LUNCH BREAK & POSTER ROUNDS & SPONSORS EXHIBITION							13:00-14:00	
14:00-15:00	Hot Topics in PanNET Treatment	Best Abstracts - Chronic Pancreatitis	EPC/IAP Acute Pancreatitis Study Group Meeting	STELLACU - CONSORTIUM									14:00-15:00	
15:00-15:45		Best Abstracts - Pancreatic Cancer											15:00-15:45	

15:45-16:15	Satellite Symposium	COFFEE BREAK & SPONSORS EXHIBITION				EPC & KPBA	COFFEE BREAK & SPONSORS EXHIBITION				15:45-16:15
16:15-17:00	Hot Topics in Cystic Tumors	YOUPIIE Session		STELLACU - CONSORTIUM	International Pancreatic Pain Consortium Meeting		EPC QoC and Guidelines Committee	EPC Research Committee Meeting		16:15-17:00	
17:00-18:00										17:00-18:00	
18:00-18:30										18:00-18:30	
18:30-19:30										18:30-19:30	

BOSPHORUS HALL

08.30-08.55	Opening Ceremony		
08.30-08.45	Welcome by the Presidents	Güralp O. Ceyhan (Istanbul, Türkiye), Vinciane Rebours (Paris, France)	
08.45-08.55	Introduction to Acibadem University & ASG	Güldal Süyen (Vice Rector of the ACU) (Istanbul, Türkiye)	
08.55-09.15	IAP - Lifetime Achievement Awardee Lecture		Chair: Kyoichi Takaori (Kyoto, Japan)
	IgG4-Related Pancreatitis: a Journey Through Time	Matthias Löhr (Stockholm, Sweden)	
09.15-10.15	Hot Topics in Pancreatology		Chairs: Patrick Michl (Heidelberg, Germany), Güralp O. Ceyhan (Istanbul, Türkiye), Kyoichi Takaori (Kyoto, Japan)
09.25-09.41	Gut-Pancreas Axis - from Microbes to Immune Cells	Albrecht Neeße (Göttingen, Germany)	
09.31-09.47	From EUS Images to Risk Scores: Artificial Intelligence and Radiomics in Endoscopic Management of Pancreatic Lesions	Silvia Carrara (Milan, Italy)	
09.47-09.59	Daraxonrasib, a RAS(ON) multi-selective inhibitor vs chemotherapy in previously treated metastatic pancreatic adenocarcinoma (mPDAC): Primary and final analysis from the Phase 3 RASolute 302 study	Christoph Springfeld (Heidelberg, Germany)	
09.59-10.15	The Mistakes I Made in My Scientific Career	Markus Lerch (Munich, Germany)	
10.15-10.45	Coffee Break		Satellite Symposium

10.45-12.00	Pancreatic Cancer - Update 2026	Chairs: Jörg Kleeff (Halle, Germany), Daniel Öhlund (Umea, Sweden), Ashok Saluja (Miami, USA)
10.45-11.00	When Tumors Starve the Body: Organ Wasting in Pancreatic Cancer	Yetiş Gültekin (Cambridge, USA)
11.00-11.15	New Class of RAS Inhibitors will Change the Therapeutic Landscape in Pancreatic Cancer	Hana Algül (Munich, Germany)
11.15-11.30	The Novel Multidisciplinary Pancreatic Cancer Guidelines - What will Change?	Elena Rangelova (Gothenburg, Sweden)
11.30-12.00	Best Pancreatic Cancer Abstract	
11.30-11.40	RNA-sequencing on EUS-acquired tissue of pancreatic cancer at diagnosis and after first-line chemotherapy allows identification of biomarkers of prognosis and response to chemotherapy: first results from the PACEUT trial	Claudia Fortunato (Milan, Italy)
11.40-11.50	Predicting disease recurrence following surgical resection of adenocarcinoma arising from intraductal papillary mucinous neoplasms (A-IPMN) using a machine learning model: Results from a multicenter study	Vivek Peddakota (Newcastle ,UK)
11.50-12.00	Intratumoral nerves drive immune suppression in pancreatic ductal adenocarcinoma via the recruitment of myeloid-derived suppressor cells	Kaan Cifcibasi (Munich ,Germany)
12.00-13.00	Satellite Symposium	
13.00-14.00	Lunch	
14.00-15.45	Hot Topics PanNET - Theranostics, Surgery & Local Ablation in PanNET: How Should We Change Practice Tomorrow?	Chairs: Katherine A. Morgan (New York, USA), Anna Caterina Milanetto (Padova, Italy), Kazushige Uchida (Kochi, Japan)
14.00-14.15	Liquid Biopsies in PanNET: NETest, cfDNA and ctDNA to Guide Surveillance and Early Intervention	Roberta Elisa Rossi (Milan, Italy)
14.15-14.30	Designing the Next Generation of Adjuvant and Neoadjuvant Trials in PanNET: Learning from Advanced Disease	Katherine A. Morgan (New York, USA)
14.30-14.45	G3 PanNET versus NEC: When Does Surgery Still Make Sense?	Mert Erkan (Istanbul, Turkiye)
14.45-15.00	Surgery for Multimetastatic PanNET with Liver Metastases: How Far is Too Far?	Claudio Ricci (Bologna, Italy)
15.00-15.15	Theranostics in PanNET: Optimising PRRT and Emerging Radioligand Strategies	Louis de Mestier (Paris, France)
15.15-15.30	EUS Ablation vs Surgery for Insulinomas and Small NF-PanNETs: Complications, Long-Term Control and Quality of Life	Stefano F. Crinò (Verona, Italy)
15.30-15.45	Best PanNET Abstracts	

15.30-15.39	Prediction of pancreatic neuroendocrine tumor grading using an artificial intelligence-based video analysis model (GradAINet) applied to contrast-enhanced endoscopic ultrasound videos	Matteo Tacelli (Milano ,Italy)
15.39-15.48	Spatial and temporal intratumor heterogeneity of Pancreatic neuroendocrine tumors (PanNETs)	Zaima Afzal Awan (Clichy ,France)
15.45-16.15	Coffee Break	Satellite Symposium
16.15-18.30	Cystic Tumors of the Pancreas 2025: Precision Stratification, Molecular Profiling & Next-Generation Management	Chairs: Roberto Salvia (Verona, Italy), Djuna Cahen (Amsterdam, Netherlands) Masafumi Nakamura (Fukuoka, Japan)
16.15-16.35	What Can We Expect from the Novel Multidisciplinary Guidelines?	Djuna Cahen (Amsterdam, Netherlands)
	Rethinking Guidelines	
16.35-16.50	BD-IPMN: Stop or Continue Surveillance?	Masayuki Kitano (Wakayama, Japan)
16.50-17.05	Main-duct IPMN: still "Resect All"?	Giovanni Marchegiani (Padova, Italy)
17.05-17.20	MCN and SPN: Selective Surgery vs Classical Dogma	Christopher Wolfgang (New York, USA)
	Molecular Subtypes, Risk Stratification & AI Future	
17.20-17.35	Molecular Roadmaps of Pancreatic Cystic Neoplasms: From KRAS to Multi-Omics	Claudio Luchini (Verona, Italy)
17.35-17.50	Beyond Cyst Size: Liquid and EUS Biopsies to Predict Malignant IPMN	Dong-Wang Seo (Soeoul, South Korea)
17.50-18.05	AI for Pancreatic Cysts: Beating the Guidelines at Predicting Malignancy	Tamas Gonda (New York, USA)
18.05-18.30	Best Cystic Tumors Abstracts	
18.05-18.14	Downregulation of circulating miR-101 and miR-451a as Early Indicators of IPMN Progression to PDAC	Chiara Corradi (Pisa ,Italy)
18.14-18.23	The mechanism of three-dimensional proliferative progression of IPMN identified by spatial transcriptome analysis of patient-derived organoids	Masahiro Shiihara (Miyagi ,Japan)
18.23-18.32	A multi-layer perceptron model for multi-omics data integration in IPMN-to-PDAC progression and transition	Giulia Peduzzi (Pisa ,Italy)

TOPKAPI HALL		
10.45 - 12.00	Best Abstracts - Acute Pancreatitis	Chairs: Dilek Oğuz (Kırıkkale, Turkiye), Robert Sutton (Liverpool, UK)
10.45-10.54	Incidence and diagnosis of disrupted pancreatic duct in acute necrotizing pancreatitis: a nationwide multicenter prospective cohort study (POLAR study)	Hannah Sopic Pauw (Nieuwegein ,The Netherlands)

10.54-11.03	Machine Learning-Based Stratification to Guide the Use of Endoscopic Ultrasound in Idiopathic Acute Pancreatitis: Prospective Validation of the Microlithiasis Prediction Score	Simon Sirtl (Munich ,Germany)
11.03-11.12	Peripheral opioid antagonism does not affect inflammatory biomarker response in Acute Pancreatitis: Insights from a multicenter, randomized, controlled trial	Amer Hadi (Hvidovre ,Denmark)
11.12-11.21	Macrophage-derived Cathepsin S links pancreatic inflammation to neuronal CREB signaling and pain	Okan Safak (München ,Germany)
11.21-11.30	Potentiation of PMCA activity by methylene blue can attenuate alcohol-induced acute pancreatitis	Zsófia Horváth (Szeged ,Hungary)
11.30-11.39	Calcium-sensing receptor inhibition alleviates acute pancreatitis by attenuating calcium overload and modulating immunity	Robert Sutton (Liverpool, UK)
11.39-11.48	Cholesterol as a determinant of pancreatic disease progression. A post-hoc analysis of prospectively collected longitudinal data	Mónika Lipp (Budapest ,Hungary)
11.48-11.57	Role of the ER-cargo protein CLN8 in the pathophysiology of acute pancreatitis	Lukas Zierke (Greifswald, Germany)
13.00-14.00	Lunch	
14.00 - 15.00	Best Abstracts - Chronic Pancreatitis	Chairs: Murat Saruç (Istanbul, Türkiye), Christoph Michalski (Heidelberg, Germany)
14.00-14.10	The French PRSS1 cohort: Natural history of hereditary pancreatitis - The PARADISIO-1 Study	Guillaume Cléry (Paris ,France)
14.10-14.20	The Silent Burden of Painless Chronic Pancreatitis: Insights from the ITARECIPE Prospective Registry	Gabriele Capurso (Milan ,Italy)
14.20-14.30	A Clinical Risk Score for Early Thrombosis Detection in Acute and Chronic Pancreatitis: Insights From a Large Cohort Study	Jakob Vielhauer (Munich ,Germany)
14.30-14.40	Restoring ductal CFTR function as a disease-modifying strategy in chronic pancreatitis	Tamara Madácsy (Szeged ,Hungary)
14.40-14.50	Macrophage Piezo1 sustains pancreatic stellate cell activation via purine metabolism to promote chronic pancreatitis progression	Jie Wu (Beijing ,China)
14.50-15.00	NMDAR1A- and IL-10-centered Neuroimmune Targeting Breaks the Pain Cycle in Chronic Pancreatitis	Nedim Can Cevik (Istanbul ,Türkiye)
15.00 - 15.45	Best Abstracts - Pancreatic Cancer	Chairs: Özlem Er (Istanbul, Türkiye), Rouzzana Giesert Istvanffy (Munich, Germany)
15.00-15.09	Reduced CFTR expression promotes pancreatic tumor progression in mice and is associated with metastasis and worse survival in human pancreatic cancer	Eva C. Vaquero (Barcelona ,Spain)
15.09-15.18	Impact of DNA Damage Repair (DDR) genes germline pathogenic variants (gPV) in metastatic pancreatic cancer patients (pts) receiving Nab-Paclitaxel / Gemcitabine (AG) or Cisplatin, Nab-Paclitaxel, Capecitabine and Gemcitabine (PAXG) first line therapy	Guido Giordano (Foggia ,Italy)
15.18-15.27	Co-evolution of Oncogenic KRAS Signaling and LILRB-high Macrophages Drives Pancreatic Cancer Recurrence	Jianzhen Lin (Nanjing ,China)
15.27-15.36	Unraveling The Role of CXCL8 in Pancreatic Cancer-Schwann Cell Crosstalk: Mechanisms of Neuroinvasion and Therapeutic Targeting	Tayyar Emir Gözeler (İstanbul ,Türkiye)
15.36-15.45	Survival impact after resection for postoperative recurrence or metastasis of pancreatic ductal adenocarcinoma analyzed using a time-dependent cox regression model	So Yamaki (Hirakata ,Japan)
15.45-16.15	Coffee Break	

16.15-18.30	YOUPIE SESSION The Game of Pancreas: Mastering Pancreatology from Basics to Youppie Throne	Chairs: Lucia Guilabert (Elche, Spain), Sara Nikolić (Maribor, Slovenia)
16.15-16.20	Case Presentation	Lucia Guilabert (Elche, Spain), Sara Nikolić (Maribor, Slovenia)
16.20-16.30	Kicking Off Strong: The Initial Management of Acute Pancreatitis	Catalina Vladut (Bucharest, Romania)
16.30-16.40	Feed Me Right: Nutrition in Acute Pancreatitis	Nina Blažević (Zagreb, Croatia)
16.40-17.00	Trouble Ahead: Managing Complications Like a Pro	Giacomo Rizzo (Sicily, Italy), Thomas Hank (Heidelberg, Germany)
17.00-17.10	Life After the Storm: Post-Acute Pancreatitis Consequences	Veronika Lillik (Budapest, Hungary)
17.10-17.20	Discussion and Questions	
	Future in Focus: Empowering Young Pancreatologists	
17.20-17.27	Pancreas 2000 Project The BYOB study, Body Composition and Outcomes in Acute and Chronic Pancreatitis: a Pancreas2000 Multicentre Study	Hanna Paw (Utrecht, Netherlands)
17.27-17.34	Pancreas 2000 Project The MEPAC Study: Oligometastatic Pancreatic Cancer Surgically Treated	Roberto Montorsi (Verona, Italy)
17.34-17.46	From the Medical Crib: Shapping the Pancreatologists of Tomorrow – a JPC Success Story	Julia Straesser (Kiel, Germany)
	EPC Fellowships	
18.01-18.06	EPC Fellowship	Kasper Overbeek (Rotterdam, Netherlands)
17.46-17.51	EPC Fellowship Bridging the Gap from Clinical Practice to Academic Pancreatology	Laura Gutiérrez-Rios (Barcelona, Spain)
	YOUPIE THRONE	
17.51-18.00	Male Youppie Awardee The Rolling Stone in 2026 – Towards an Individualized Biliary Pancreatitis Therapy	Simon Sirtl (Munich, Germany)
18.00-18.10	Female Youppie Awardee The “Translational Endoscopist”: a Mythological Figure to Tackle Pancreatic Cancer	Livia Archibugi (Milan, Italy)
GALATA HALL		
10.45-13.00	Best Abstracts Varia-I	Chairs: Nevin Oruç (Izmir, Türkiye), Roberto Montorsi (Verona, Italy)
10.45-10.54	Loss of CFTR enhances mesenchymal traits and lysosome dysfunction in pancreatic stellate cells	Raquel Ibañez (Lleida, Spain)
10.54-11.03	Differentiating pancreatic cancer and chronic pancreatitis: a novel MDCT postprocessing approach	Konstantin Lesko (Moscow, Russia)
11.03-11.12	Systematic Review and Meta-analysis of Health-Related Quality of Life Outcomes after Total Pancreatectomy and Islet Auto-transplantation	Vivek Peddakota (Newcastle, UK)
11.12-11.21	Using GWAS and AI-Based Regulatory Models to Prioritize Pancreatic Cancer Risk Variants for Functional Studies	Pelin Ünal (Antalya, Türkiye)

11.21-11.30	A Pancreas Phantom mimicking natural pancreatic mechanical properties: bridging engineering and endoscopic ultrasound for reproducible Shear Wave Evaluation	Maria Terrin (Milan ,Italy)
11.30-11.39	Endoscopic Therapy and Laser Lithotripsy for Painful Idiopathic Chronic Pancreatitis: A Five-Year Single-Centre Experience from South India — Outcomes, Stone Clearance, and Predictors of Response	Rizwan Ahamed (Ernakulam ,India)
11.39-11.48	Whole exome sequencing identifies a genetic signature for intraductal papillary mucinous neoplasm evolution into pancreatic ductal adenocarcinoma	Sinan Saglam (Pisa ,Italy)
11.48-11.57	Multiparametric Endoscopic Ultrasound (EUS) for solid pancreatic tumors: added value of detective flow imaging (DFI) to Elastography and Contrast Enhancement (CE-EUS)	Rodrigo Montoto Meijide (Santiago de Compostela ,Spain)
11.57-12.06	Pancreas and Islet Transplantation versus Insulin Therapy in patients with Type 1 Diabetes undergoing Renal Transplantation: A Systematic Review and Meta-Analysis	Arnold Marchis (Budapest ,Hungary)
12.06-12.15	Intratumoral Microbiome Composition Differs Across Gastrointestinal Cancer Types: Insights from a Contamination-Controlled 16S Approach	Emel Comak (Tübingen ,Germany)
12.15-12.24	Modeling pressure-dependent epithelial cell responses in human pancreatic apical-out organoids	Aletta Kata Kiss (Szeged ,Hungary)
12.24-12.33	Analysis of deep neural networks in the differentiation and endosonographic diagnosis of focal lesions of the pancreas	Barbara Wlodarczyk (Lodz ,Poland)
12.33-12.42	Evaluation of genetic testing discussions and referral pathways in pancreatic cancer: adherence to NICE NG85 and the NHS Genomic Test Directory (R367)	Sumaiya Sayed (Stoke On Trent ,United Kingdom)
12.42-12.51	Imaging biomarkers tracking chronic pancreatitis progression - a 4-year prospective multiparametric MRI study	Sigrid Bergmann (Aalborg ,Denmark)
12.51-13.00	Development of an Artificial Intelligence Model to Predict Preoperative Islet Yield During Total Pancreatectomy and Islet Autotransplantation (TPIAT)	Vivek Peddakota (Newcastle ,UK)
13.00-14.00	Lunch	
14.00-15.45	Acute Pancreatitis Study Group - EPC/IAP 2026 Session	Chair: Sanjay Pandanaboyana (Newcastle Upon Tyne, UK)
14.00-14.15	Rabi-767 Study	Timothy Gardner (New Hampshire, USA)
14.15-14.30	Insights into Mechanisms of Systemic Effects of Acute Pancreatitis from Analysis of Serum Proteins	Aditi Bhargava (California, USA)
14.30-14.45	A Global Phase 3 Trial of Auxora in Acute Pancreatitis	Robert Sutton (Liverpool, UK)
14.45-15.00	CAPPOS Project	Louise Kuhlmann (Aalborg, Denmark)
15.00-15.15	Studies from Newcastle Pancreas Study Group: SARCOPANC/OXIPANC/PANCPLEURAL studies	Sanjay Pandanaboyana (Newcastle Upon Tyne, UK)
15.15-15.30	Studies from the Dutch Pancreatitis Study Group (PLANCTON, PICUS-2)	Lars VanderBroeck (Utrecht, The Netherlands), Rolf Schwartz (Utrecht, The Netherlands)
15.30-15.45	Studies from the Hungarian Pancreatic Study Group (PANCA, PPDM, ARPAD, LIFESPAN, EFFORT, PROSECCO)	Bálint Eröss (Budapest, Hungary)
15.45-16.00	Balanced Solution Versus Normal Saline in Acute Pancreatitis: What's Next?	Lu Ke (Shenyang, China)

TAKSİM HALL		
08.55-09.10	Welcome and Strategic Framing	
	From StellaTUM to StellACU: What the Next-Generation PSC/CAF Consensus Must Deliver	Mert Erkan (Istanbul, Turkiye)
09.10-10.15	Session 1: PSC States, Heterogeneity and Plasticity in Pancreatic Disease	Chairs: Atsushi Masamune (Sendai, Japan)
09.10-09.25	Origins to States: Stellate Cell Activation and Role in Pancreatitis	Minoti Apte (Sydney, Australia)
09.25-09.40	PSC/CAF role in Pancreatic Cancer - Inflammatory CAF Programs and Senescence	Shin Hamada (Sendai, Japan)
09.40-09.55	CAF State Frameworks: A Minimal Taxonomy Compatible Across Studies and Technologies	Raghu Kalluri (Houston, USA)
09.55-10.15	Discussion and Outputs	
10.15-10.45	COFFEE BREAK	
10.45-12.30	Spatial Biology, ECM Architecture and CAF Function	Chairs: Bo Kong (Heidelberg, Germany), Irene Esposito (Dusseldorf, Germany)
10.45-11.00	The Role of Stroma in Early Pancreatic Carcinogenesis	Jörg Kleeff (Halle, Germany)
11.00-11.15	Stromal Architecture Through a Clinical Lens: Impact of ductal drainage on carcinogenesis and diabetes	Mert Erkan (Istanbul, Turkiye)
11.15-11.30	Neurostromal Interactions in PDAC	Ekin Demir (Munich, Germany)
11.30 -11.45	Pancreatic Cancer Related Diabetes (PCRD) : PSC-Islet Interactions in PDAC	Chamini Perera (Sydney, Australia)
11.45-12.00	CAF Heterogeneity and Immune Modulation in PDAC	William L. Hwang (Boston, USA)
12.00-12.15	Wrap-up and Outputs	
13.00-14.00	LUNCH BREAK	
14.00-15.25	Session 3: Models, Technologies, Translation and Trial Design Part A: Models and Technologies	Chairs: Raghu Kalluri (Houston, USA), Hana Algül (Munich, Germany)
	Part A: Models and Technologies	
14.00-14.10	Organoid and Developmental PDAC Models	Matthias Hebrok (Munich, Germany)
14.10-14.20	Human-Relevant Systems and Clinical Integration	Mattias Löhr (Stockholm, Sweden)
14.20-14.30	Standardised Experimental Models to Assess CAF-Cancer interactions	Bo Kong (Heidelberg, Germany)
14.30-14.40	AI-Guided Spatial Oncology	Kıvanç Görgülü (Munich, Germany)
	Part B: Translation and Clinical Trial Design	
14.40-14.50	From Preclinical Endpoints to Clinical Reality: Stromal Targeting and CAF-Informed Trials	Hana Algül (Munich, Germany)
14.50-15.00	Pathology-Based Biomarkers of CAF Heterogeneity	Irene Esposito (Dusseldorf, Germany)
15.00-15.10	AI-Guided Spatial Oncology	Joo Kyung Park (Seoul, South Korea)
15.10-15.25	Wrap-up and Outputs Purpose: Quick Q&A and transition to Panel	
15.55-16.40	COFFEE BREAK	

15.55-16.40	Structured Panel: Trial Design Convergence	Chair: Helmut Friess (Munich, Germany)
	Finalised principles for CAF-informed trial design; Consensus biomarker package; Agreed trial endpoint framework	Mert Erkan (Istanbul, Turkiye), Irene Esposito (Dusseldorf, Germany), Minoti Apte (Sydney, Australia), Atsushi Masamune (Sendai, Japan), Mathias Löhr (Stockholm, Sweden)
16.40-17.40	Final Consensus Consolidation and Voting	Chair: Minoti Apte (Sydney, Australia), Atsushi Masamune (Sendai, Japan)
	Voting on terminology and reporting standards Confirmation of model and functional prioritisation Agreement on trial principles Writing group formation Delphi and manuscript timeline confirmation	
KADIKÖY HALL		
13.00-14.00	SBPC Meeting	
16.15-17.00	International Pancreatic Pain Consortium Meeting	

A1 ROOM			
13.00-14.00	SBG Meeting		
15.45-16.15	EPC & KPBA		
A2 ROOM			
10.15-10.45	MEPAC Investigators' Meeting		
16.15-17.00	EPC Public Affairs Committee		
18.00-19.30	EPC Quality of Care and Guidelines Committee		
A3 ROOM			
18.30-19.30	EPC Research Committee Meeting		
SULTANS ROOM			
07.00-08.30	EPC - Council Meeting		
Bebek Poster Hall / 13.00 - 14.00			
*Please kindly note that each presentation is allocated 4 minutes (3-minute presentation + 1-minute discussion)			
AbsRef	Pub Number	Title	Presenter
Group -1		Chairs: Masayuki Kitano (Wakayama, Japan), Nuria Malats (Madrid, Spain)	
89	PPCC-001	Vascular resection in robotic pancreaticoduodenectomy for pancreatic cancer: a propensity score-matched study	Bor Uei Shyr

90	PPCC-002	Impact of mesopancreas dissection level 3 in robotic pancreaticoduodenectomy for pancreatic head cancer - a propensity score-matched study	Bor Shiuian Shyr
94	PPCC-003	Results of surgical treatment of ductal adenocarcinoma of the head of the pancreas with involvement of the main vessels and involvement of the vascular margins of resection	Andrii Savytskyi
95	PPCC-004	Impact of Feeding Jejunostomy on Postoperative Outcomes After Whipple's Procedure: A Comparative Propensity Score Analysis Using the Comprehensive Complication Index	Rohith Kodali
105	PPCC-005	Förster Resonance Energy Transfer (FRET) Nanoprobe can diagnose Pancreatic Juice Activation from Postoperative Pancreatic Fistula	Satoshi Mizutani
119	PPCC-006	Setting the Optimal Arterial Divestment Outcomes in Pancreatic Surgery	Susanna Tondato
123	PPCC-007	Differential Diagnostic Criteria for Pancreatic Adenocarcinoma vs. Chronic Pancreatitis: A Morphological Study	Natalia M. Honcharova
124	PPCC-008	Diagnostic Efficacy of TGF- β 1 and CA 19-9 in Distinguishing Benign from Malignant Pancreatic Lesions	Natalia M. Honcharova
173	PPCC-009	Preoperative Tooth Count Predicts Long-Term Survival After Curative Resection for Pancreatic Ductal Adenocarcinoma: A Retrospective Cohort Study	Kenichiro Uemura
185	PPCC-010	Pattern and risk factors for postoperative recurrence in borderline resectable pancreatic cancer after upfront surgery	Han Xuan Wang
186	PPCC-011	Intrapancreatic Fat Deposition on Pre-diagnostic Non-contrast CT Is Independently Associated with Pancreatic Ductal Adenocarcinoma	Arjun Chatterjee
196	PPCC-013	The Impact of Body Mass Index on Predicting Postoperative Pancreatic Fistula in Relation to Pancreatic Texture and Main Pancreatic Duct Diameter After Pancreaticoduodenectomy	Kostiantyn Kopchak
198	PPCC-014	The clinical significance of CAPRIN-1 expression in patients with resectable and borderline resectable pancreatic ductal adenocarcinoma underwent pancreatectomy	Sang Thanh Nguyen
201	PPCC-015	Cancer aggregation beyond the pancreas in families with familial pancreatic cancer: a population-based comparison using the Italian Registry of Families At Risk of Pancreatic Cancer data	Erica Secchettin
203	PPCC-016	Longitudinal changes in triceps skinfold thickness and serum albumin during chemotherapy in patients with pancreatic cancer: Sex-based prognostic insights	Jongkyun Lee
Group - 2		Chairs: Albrecht Neeße (Göttingen, Germany), Helmut Friess (Munich, Germany)	
210	PPCC-017	Impact of chemotherapy dose-intensity and protocol guidelines violations on neoadjuvant treatment outcome in pancreatic ductal adenocarcinoma	Anna Fosfuri
214	PPCC-019	Beyond Incidence: Changing Sex Dynamics and the Expanding Population Burden of Pancreatic Cancer in Hungary	Gábor Mohácsi
262	PPCC-020	Serum MMP-8 and TIMP-1 as prognostic factors in pancreatic ductal adenocarcinoma	Ella Kesti
274	PPCC-021	Minimally Invasive Pancreatectomies for Pancreatic Tumors	Igor Khomiak
275	PPCC-022	Genomic determinants of relapse and survival in early stage and metastatic pancreatic ductal adenocarcinoma	Beatrice Mohelnikova Duchonova

279	PPCC-023	Healthcare Expenditures Across the Care Continuum of Pancreatic Cancer and Resected Precursor Lesions in the Netherlands	Djuna L. Cahen
288	PPCC-024	Preoperative CA 19-9 and Prognosis in Resectable Pancreatic Ductal Adenocarcinoma	Rayhan Rejeb
290	PPCC-025	High Preoperative CA 19-9 Predicts Early Recurrence and Metastatic Patterns in Pancreatic Ductal Adenocarcinoma	Rayhan Rejeb
291	PPCC-026	Intratumoral expression of cytidine deaminase (CDA) in resected pancreatic ductal adenocarcinoma (PDAC)	Nils Oskar Elander
302	PPCC-027	Age-adjusted Charlson Comorbidity Index (ACCI) Predicts Adjuvant Therapy after Resection for Pancreatic Ductal Adenocarcinoma	Kira Meißner
309	PPCC-028	Preoperative CA 19-9 as a Predictor of Surgical Margin Status and Survival in Resectable Pancreatic Ductal Adenocarcinoma	Rayhan Rejeb
310	PPCC-029	Impact of Postoperative Complications on Survival in Resectable Pancreatic Ductal Adenocarcinoma	Rayhan Rejeb
316	PPCC-030	Body surface gastric mapping to determine patterns of gastric electrical activity associated with delayed gastric emptying after pancreaticoduodenectomy	Sanjay Pandanaboyana
317	PPCC-031	Tumor budding assessment in pancreatic carcinoma: automated evaluation using digital pathology in a low-resource setting	Myriam Ayari
355	PPCC-034	Apolipoprotein A2 isoforms as blood biomarkers reflecting pancreatic exocrine function: clinical implications for IPMN and post-pancreatectomy steatotic liver disease	Kazufumi Honda
Group - 3		Chairs: Takao Ohtsuka (Kagoshima, Japan), Başak Oyun Uluç (Istanbul, Türkiye)	
363	PPCC-035	Conversion Surgery for Unresectable Pancreatic Ductal Adenocarcinoma with Liver Metastasis: A Nationwide Multicancer Study	Daisuke Hashimoto
390	PPCC-036	Gut microbiota differentiates chronic pancreatitis from pancreatic ductal adenocarcinoma and indicates alterations in short chain-fatty acid metabolism	Jacob Hamm
395	PPCC-037	The method "Arterial resection (AR) and reconstruction before mobilization of the pancreas" (ARRBMP) for locally advanced pancreatic cancers (LAPDAC) surgery. Results of 183 arterial segments resections in 121 patients	Viacheslav Egorov
399	PPCC-038	Three types of arterial anatomy after spleen-preserving distal pancreatectomies (SPDP) with splenic vessels resection(SVR). How to use this knowledge for organs' preservation in treatment of locally advanced pancreatic head cancers (LAPHC)	Viacheslav Egorov
400	PPCC-039	The rise of pancreatic cancer mortality in Italy: a call for urgent healthcare action. Ten-year National and regional forecasts until 2035	Samuele Grandi
406	PPCC-040	Prognostic immune nutritional index is a valuable prognostic marker in advanced pancreatic cancer	Mariia Kiriukova
416	PPCC-041	Tumor response scoring systems for pancreatic ductal adenocarcinoma: Systematic Review and Meta-analysis	Roberta Vella
417	PPCC-042	Optimization of treatment strategies for patients with borderline resectable and locally advanced pancreatic cancer	Liudmyla Pererva

420	PPCC-043	Comparing pre-treatment systemic inflammation and sarcopenia in pancreatic cancer	Myriam Ayari
427	PPCC-044	Who achieves long-term survival after pancreatoduodenectomy for pancreatic cancer? A single-center analysis of prognostic factors	Pavel Skalicky
430	PPCC-045	Prevention strategies and treatment of postoperative complications after pancreatoduodenectomy	Volodymyr Kopchak
433	PPCC-046	Uncovering the hidden fat: myosteatosi s as a novel prognostic marker in pancreatic adenocarcinoma	Myriam Ayari
444	PPCC-047	From Radiological to Biological Resectability: A Prognostic Shift via cfDNA Fragmentomics in Pancreatic Cancer	Lingdi Yin
446	PPCC-048	Postoperative and survival implications of standard and extended surgery compared to non-resectional procedures for localized pancreatic ductal adenocarcinoma	Fabio Casciani
450	PPCC-049	Nine-year temporal treatment trends and prognostic factors of survival after resection for pancreatic malignant epithelial tumors: a 3,137-case single-center retrospective study	Kuirong Jiang
Group - 4 Chairs: Patrick Michl (Heidelberg, Germany), Lena Seifert (Dresden, Germany)			
452	PPCC-050	Pancreatic Cancer in the Uncinate Process with Vascular Involvement: An International Multicenter Study of Surgical and Oncological Outcomes after Neoadjuvant Therapy	Hiroyuki Ishida
473	PPCC-051	Circulating tumor DNA in pancreatic cancer: time to adopt in clinical practice	Filipe Castro Borges
481	PPCC-052	Radicality in pancreatoduodenectomy: where the east meets the west	Inês Faria Teixeira
492	PPCC-053	Pancreatic Cancer Derived Organoids Allow Personalised Drug Screening	Wei Liu
493	PPCC-054	Neoadjuvant Chemotherapy Versus Upfront Surgery for Pancreatic Ductal Adenocarcinoma with CT-Suspected Vascular Invasion: Association with Overall Survival and Microvascular Invasion Response	Jianzhen Lin
495	PPCC-055	Prognostic Value of Lymph Node Ratio After Curative Resection for Pancreatic Ductal Adenocarcinoma	Manel Yakoubi
501	PPCC-056	A Rare Case: Primary Pancreatic Lymphoma	İsmail Atasoy
502	PPCC-057	Pancreatic juice lipidomic profiling for prognostic stratification in pancreatic ductal adenocarcinoma	Elena Desiato
508	PPCC-058	Metastasis-directed ablative treatment in addition to systemic chemotherapy in oligometastatic pancreatic ductal adenocarcinoma: A systematic review and meta-analysis	Melinda Piri
525	PPCC-059	Socioeconomic Deprivation Adversely Affects the Routes to Diagnosis and Long-term Outcomes in Patients with Pancreatic Ductal Adenocarcinoma	Vivek Peddakota
544	PPCC-060	Cardiovascular Risk in Pancreatic Cancer: A Meta-analysis of 197 Studies	Jázmin Németh
557	PPCC-061	Neoadjuvant Therapy Fails to Improve Survival Compared with Upfront Surgery in Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis of Randomized Clinical Trials	Tamás Tölgyes

561	PPCC-062	Negative prognostic implication of HER2 expression in the first-line chemotherapy for advanced pancreatic cancer	Shih Hung Yang
569	PPCC-063	IRE-centered MDT enabled long-term survival and renewed benefit after repeat IRE in unresectable locally advanced pancreatic cancer: a case report	Yingjie Wang
571	PPCC-064	Hemoglobin A1c Levels and the Risk of Pancreatic Ductal Adenocarcinoma. A Systematic Review and Meta-analysis	Zsófia Román
Group - 16			
Chairs: Viktória Venglovecz (Szeged, Hungary), Dilara Turan (Ankara, Turkiye)			
103	PCPC-001	Spectrum and Determinants of Acute and Chronic Pancreatitis in Choledochal Cysts	Zeeshan Ahmed
128	PCPC-002	Paraduodenal Pancreatitis Complicated by Intramural Duodenal Hematoma and Gastrointestinal Hemorrhage	Tuğba Tolu Bülte
149	PCPC-003	Red ginseng supplements improve quality of life in patients with mild chronic pancreatitis symptom	Jikon Ryu
155	PCPC-004	Autoimmune pancreatitis associated with IgG4-related disease relapses more often than expected, what are their risk factors? Evidence from a large french cohort	Clémence Descourvières
192	PCPC-005	A subgroup of chronic pancreatitis patients exhibits a hyperinflammatory phenotype characterized by upregulated IL-6/IL-17 axis signalling	Rasmus Hagn Meincke
209	PCPC-006	Pancreatic quantitative sensory testing for pain assessment in Indian patients with chronic pancreatitis	Misbah Unnisa
216	PCPC-007	Complete longitudinal dissection of the Wirsung's duct and its mouth with the formation of an isolated pancreatodigestive anastomosis in patients with chronic pancreatitis with pancreatic ductal hypertension	Andrii Klymenko
218	PCPC-008	Multimodal management of hemosuccus pancreaticus secondary to chronic pancreatitis: A 10-year single-center experience	Vladyslav Shatalo
232	PCPC-009	Adenosquamous carcinoma complicating chronic calcifying pancreatitis: a case report	Manel Yakoubi
253	PCPC-010	Prevalence and risk factors for malnutrition and sarcopenia in chronic pancreatitis	Samanvith Patlori
285	PCPC-011	Long-term efficacy of a modified non-flared fully covered metal stent for refractory main pancreatic duct stricture in chronic pancreatitis: Result of a 6-year follow-up study	Jong Ho Moon
295	PCPC-012	Differentiation of autoimmune pancreatitis from pancreatic adenocarcinoma using PET/CT features: a systematic review and updated meta-analysis	Sung Hoon Moon
311	PCPC-013	Autoimmune Pancreatitis Associated with IgG4-Related Disease: A Case Series of Four Patients	Rayhan Rejeb
326	PCPC-014	Search for the ideal biomarker of autoimmune pancreatitis	Irina Savina
268	POTH-009	A comparison of diagnostic scoring systems for type 1 autoimmune pancreatitis including the International Consensus Diagnostic Criteria (ICDC)	Tamara Vijfhuizen
Group -17			
Chairs: Ayşe Nurdan Tözün (İstanbul, Türkiye), Kasper Overbeek (Rotterdam, Netherlands)			

335	PCPC-015	Genotypic and phenotypic characterization of CEL-HYB1 carriers in chronic pancreatitis	Renate Valdersnes Seierstad
340	PCPC-016	The clinical course of hereditary pancreatitis in children with p.R122C mutation of the PRSS1 gene	Grzegorz Oracz
344	PCPC-017	Sarcopenia in patients with chronic pancreatitis	Mila Kovacheva Slavova
372	PCPC-018	Treatment of Chronic Pancreatitis with Benign Common Bile Duct Stricture	Igor Khomiak
376	PCPC-019	Preprocedural CT-Based Risk Stratification for Peroral Pancreatoscopy-Guided Lithotripsy in Pancreatic Duct Stones	Seok Ho Dong
402	PCPC-020	Fecal pancreatic elastase-1 as a potential indicator for risk stratification of post-chronic pancreatitis diabetes mellitus: a multicenter cross-sectional study	Yuruchen Zhu
407	PCPC-021	Pancreatico-portal venous fistula in pancreatitis: insights on clinicoradiological profile and outcomes from a large single-center cohort	Chandan Peddapulla
424	PCPC-022	Fully covered metal stent usage in the treatment of pancreatic duct stenosis in chronic pancreatitis	Bengi Ozturk
574	PCPC-023	Early chronic pancreatitis as a distinct stage in the pancreatitis continuum	Viktória Venglovecz
578	PCPC-024	The multidimensional burden of chronic pancreatitis on health-related quality of life (HRQoL)	Emilija Nikolovska Trpchevska
624	PCPC-025	Pancreatic Cancer in Chronic Pancreatic Inflammatory Diseases: Risk and Clinicopathological Characteristics	Tsukasa Ikeura
679	PCPC-026	Disease stage-related associations of depression, anxiety, alcohol, and smoking in pancreatitis	Judit Lippai
738	PCPC-027	Longitudinal clinical characteristics of a misfolding-causing mutation (PRSS1 p.L104P) associated hereditary pancreatitis	Balázs Csaba Németh
257	POTH-008	A Case of Dorsal Pancreatic Agensis	Civanmert Bayrak
391	POTH-015	Therapeutic and Diagnostic Determinants in Autoimmune Pancreatitis: Steroid Induction Dosing and Criteria Framework Evaluation	Motaz Ashkar

Moda Poster Hall / 13.00 - 14.00

*Please kindly note that each presentation is allocated 4 minutes (3-minute presentation + 1-minute discussion)

AbsRef	Pub Number	Title	Presenter
Group - 5		Chairs: Hana Algül (Munich, Germany), Chiara Falcomatà (New York City, USA)	
111	PPCE-001	Stage-Specific Roles of PLA2G6 in Pancreatic Cancer Initiation and Progression	Zihan Chen
116	PPCE-002	Identification of an IDO-1 inhibitor reducing growth of pancreatic ductal adenocarcinoma cells, but with little effect on surrounding stromal cells	Leon Heffinger
157	PPCE-003	MicroRNA-mediated regulation of FXRD3 and its implications for PDAC progression	Ke Xin Yee
164	PPCE-004	GARP Orchestrates Tumor Progression, Immune Suppression, and EMT Remodeling in Pancreatic Ductal Adenocarcinoma	Paul David

165	PPCE-005	CD86 Orchestrates B-Cell Activation in PDAC and Provides a Novel Blood-Based Biomarker for Disease Aggressiveness	Paul David
166	PPCE-006	Compartment-Specific Roles of CD44 in Pancreatic Cancer: Integrated Analyses of Lymph Nodes, Circulating Exosomes, and Tumor Immunogenomics	Alara Karabiber
174	PPCE-008	CPT1A-mediated Fatty Acid Oxidation Drives A Classical Epithelial State in Pancreatic Cancer	Guangfu Wang
180	PPCE-009	Targeting tumor-derived collagen to mitigate pancreatic cancer aggressiveness	Donatella Delle Cave
213	PPCE-010	Blood biomarker discovery for early detection of pancreatic cancer using Proximity Extension Assay	Ayumi Kashiro
234	PPCE-011	Identifying the appropriate organoid-based culture system for drug testing in Pancreatic Ductal Adenocarcinoma	Christine Sophia Nitschke
235	PPCE-012	Early-onset chronic pancreatitis alters the trajectory of dysplasia associated with oncogenic KRAS	Rebecca Reardon Lochbaum
244	PPCE-013	Landscapes of Protein Posttranslational Modifications in Pancreatic Cancer	Yunfeng Shan
247	PPCE-014	Chimeric antigen receptor macrophages(CAR-M) targeting claudin18.2 exhibit anti-tumor activity in pancreatic cancer	Qin Shang Yuan
264	PPCE-015	3D pancreatic cancer models reveal JAK/STAT3-, hypoxia- and OXPPOS-related pathways driving radioresistance	Julian Kapfer
265	PPCE-016	PKMYT1 inhibition enhances radiosensitivity in pancreatic ductal adenocarcinoma	Arlett Patricia Gloria Schäfer
Group - 6		Chairs: Francisco X. Real (Madrid, Spain), Rouzanna Giesert Istvánffy (Munich, Germany)	
266	PPCE-017	A Reciprocal IGFBP5-B4GALT5 Stromal-Tumor Axis Drives ECM Remodeling and PDAC Progression	Bolin Zhang
269	PPCE-018	Translational analysis of the intratumoral microbiome and immune cell milieu in PDAC	Katharina Tillmanns
284	PPCE-019	USP22 Promotes Treg Cell Infiltration and Modulates Immunotherapy Efficacy via the PIAS1/P65/CCL22 Pathway in Pancreatic Cancer	Aman Wang
292	PPCE-020	Validation of a dual panel RNAScope assay for identification of Classical and Basal-like molecular subtypes of pancreatic adenocarcinoma	Christelle Bouchart
312	PPCE-021	Tigecycline sensitizes pancreatic carcinoma models for TRAIL-induced apoptosis	Frank K. Braun
314	PPCE-022	Gut microbial dysbiosis is associated with distinct immune checkpoint expression patterns on CD8+ T cells	Loreen Natusch Bufe
322	PPCE-023	Investigation of FOLFIRINOX sensitivity and cellular death mechanisms in TGF- β -induced metastatic pancreatic cancer	Buse Birinci
323	PPCE-024	Biopsy-Derived Primary Cell and Organoid Models of Borderline Resectable Pancreatic Cancer for Translational Research	Nevruz Alis
330	PPCE-025	Metabolic Targeting in Pancreatic Cancer: Antitumor Activity of FX-11 and Benztropine in a PDAC Xenograft Model	Onur Onguncan
332	PPCE-026	Unravelling the heterogeneity of CAFs in PDAC reveals a novel population: Lipofibroblasts	Didem Saka
341	PPCE-027	In vivo CRISPR screening identifies immune checkpoint associated genes in pancreatic ductal adenocarcinoma	Christian Pilarsky
347	PPCE-028	Integrating Deep Learning with Functional Assays to Identify Peripherally Restricted GluN2D Inhibitors Targeting Neural Invasion in Pancreatic Cancer	Esra Nalbat
352	PPCE-029	Exosomal RNAs derived from plasma reveal PRKAG2 mRNA as a potential biomarker for pancreatic cancer in diabetic patients	Helen Binang
356	PPCE-030	Presence and functional interaction of mesenchymal stromal cells in early pancreatic carcinogenesis	Tina Seidel
357	PPCE-031	Influence of fibroblast activation on early pancreatic carcinogenesis	Mira Pasemann
Group - 7		Chairs: Jörg Kleeff (Halle, Germany), William L. Hwang (Boston, USA)	
358	PPCE-032	Bile acids enhance tumorigenic properties in pancreatic ductal adenocarcinoma via TRPV6 upregulation	Boshra Yosef
365	PPCE-033	Deciphering the Peripheral Immune Landscape in Pancreatic Cancer: Comparative Analysis and Prognostic Biomarker Discovery Using Single-Cell RNA-Sequencing	Lingdi Yin
369	PPCE-034	Targeting IRE1 α in PDAC: Therapeutic Vulnerability and Prognostic Stratification	Tamal Sarkar

378	PPCE-035	Nano-drill-Mediated ECM Remodeling Amplifies Ferroptosis for Cancer Therapy	Zengkan Du
392	PPCE-036	Lunapark and its role in endoplasmic reticulum stress and perineural invasion in pancreatic ductal adenocarcinoma	Nino Javakhishvili
398	PPCE-037	Paracrine interactions and transcriptomic insights from mouse pancreatic stellate cell (PSC) spheroid co-culture with pancreatic cancer cells	Nino Javakhishvili
403	PPCE-038	Towards a Multiscale Consensus Definition of Stromal Heterogeneity in Pancreatic ductal adenocarcinoma	Camille Pignolet
409	PPCE-040	Aspirin alters the pancreatic stellate cell secretome to suppress tumor-nerve interactions in pancreatic cancer	Sıla Sığırılı
415	PPCE-041	Pancreatic cancer fibrosis activates protumorigenic Schwann cells through a nuclear mechanosensing mechanism	Pavel Stupakov
435	PPCE-042	Chimeric antigen receptor macrophages(CAR-M) targeting claudin 18.2 exhibit anti-tumor activity in pancreatic cancer	Qin Shang Yuan
436	PPCE-043	Mapping KCMF1, PAF15 and BAG4 expression in pancreatic ductal adenocarcinoma: Associations with tumour biology and patient outcomes	Chamini Perera
468	PPCE-045	Natural killer cell cytotoxicity decreased by tumor-associated Schwann cells against pancreatic cancer cells in vitro	Taner Kasapoglu
472	PPCE-046	Isolation and Complex Characterisation of Pancreatic Cancer-Associated Fibroblasts from Human Cancer Tissue	Ivana Valicová
477	PPCE-047	Functional role of very-long chain fatty acid sphingolipids in pancreatic cancer	Tahib Habshi
480	PPCE-048	BET inhibitors as a promising therapeutic strategy for pancreatic ductal adenocarcinoma	Lucia Juhasikova
Group - 11		Chairs: İhsan Ekin Demir (Munich, Germany), Bahadır Bozkırlı (Istanbul, Türkiye)	
88	PSUR-001	Propensity score-matched comparison of robotic and laparoscopic pancreaticoduodenectomy	Bor Shiuan Shyr
91	PSUR-002	Predictive performance of drain amylase in Identifying Postoperative Pancreatic Fistula Following Robotic Pancreaticoduodenectomy	Bor Shiuan Shyr
101	PSUR-003	Enzyme replacement following total pancreatectomy: population analysis	Michal Gregorik
104	PSUR-004	Comparative efficacy of contemporary risk assessment scores in predicting risk of postoperative pancreatic fistula following distal pancreatectomy	Zeeshan Ahmed
112	PSUR-005	Vascular outcome in pancreaticoduodenectomy with vascular resection	Bor Shiuan Shyr
114	PSUR-006	Clinical impact of intraperitoneal drains after pancreatectomy	Philipp Palaras
120	PSUR-007	Magnetic assisted surgical field exposure technology can shorten the operation time and improve the safety in laparoscopic distal pancreatectomy	Liang Han
176	PSUR-009	Impact of Modified Pancreatojejunostomy Techniques on Postoperative Outcomes After Pancreatoduodenectomy	Oleksandr Kvasivka
225	PSUR-010	Postpancreatectomy diarrhoea: prospective, single-centre longitudinal analysis of incidence, risk factors, management, and impact on quality of life	Livia Zornetta
258	PSUR-011	Laparoscopic pancreaticoduodenectomy- initial experience in a high-volume centre	Elena Mihaela Vrabie
260	PSUR-012	A Systematic Review of Randomised Controlled Trials on Pain Domains and Assessment Methods in Post Pancreatectomy patients	Vivek Peddakota
273	PSUR-013	Endoscopic resection of ampullary adenomas	Igor Khomiak
282	PSUR-014	Deep learning versus pathologist assessment of pancreatic resection margins in predicting postoperative complications after pancreatoduodenectomy	Tuija Noreila
333	PSUR-016	Advanced age is not a risk factor for postoperative mortality after pancreatic surgery: results from a retrospective cohort analysis	Hans Michael Tautenhahn
Group - 12		Chairs: Sanjay Pandanaboyana (Newcastle, UK), Ibrahim Halil Gürcinar (Munich, Germany)	
349	PSUR-018	Serum Interlekin-6 on POD2 and CRP on POD3 predict postoperative pancreatic fistula after pancreatoduodenectomy	Ughur Aghamaliyev
366	PSUR-019	Safety and Efficacy of a Modified Pancreaticojejunostomy Technique in Pancreatoduodenectomy: A Retrospective Cohort Study	Wei Liu
368	PSUR-020	Robotic versus open pancreatoduodenectomy: an individual patient data meta-analysis of randomized trials	Julia Menso

370	PSUR-021	Distal pancreatectomy in the era of minimally invasive pancreatic surgery; robotic vs open. Single center retrospective study	Martin Lovecek
419	PSUR-022	Laparoscopic Subtotal Pancreatectomy: Technical Nuances and the Major Challenge of Postoperative Pancreatic Fistula – A Single-Center Experience	Sude Sezer Özkul
422	PSUR-023	Robotic versus Open Pancreatic Surgery at a University Hospital: Early Outcomes from the Implementation of a Robotic Program	Ibrahim Halil Gurcinar
425	PSUR-024	Analysis of clinical parameters for acquiring the learning curve sufficiency in robotic pancreaticoduodenectomy	Carolina González
426	PSUR-025	Robotic central pancreatectomy with pancreatic anastomosis to the gastric remnant after a gastric bypass for a pancreatic neuroendocrine tumor	Carolina González
438	PSUR-026	Minimally Invasive strategy in Pancreatic Head: Pancreaticoduodenectomy, Enucleation, or Duodenal-preserving pancreatic head resection?	Chao Lu
443	PSUR-027	Fusion of Imaging and Clinical Features for Predicting Postoperative Pancreatic Fistula after Distal Pancreatectomy: An Explainable Machine Learning Approach	Xiaofeng Xue
445	PSUR-028	Enhancing adjuvant chemotherapy tolerance in pancreatic adenocarcinoma following pancreaticoduodenectomy: Insights from minimally invasive surgery and home enteral nutrition	Yucheng Zhou
447	PSUR-029	The impact of cardiac comorbidities on postoperative outcome in pancreatic head resections- a unicenter, retrospective trial	Patricia Wyzlic
448	PSUR-030	Single vs. Double Loop Reconstruction for Pancreatic and Biliary Anastomoses in Pancreaticoduodenectomy: A Meta-Analysis of Randomized Controlled Trials	Cüneyt Kayaalp
449	PSUR-031	High-Risk Pancreatic Anastomosis vs. Total Pancreatectomy in Pancreatoduodenectomy: A Meta-Analysis	Cüneyt Kayaalp
454	PSUR-032	Surgical Outcomes of Pancreatoduodenectomy in Octogenarians	Cüneyt Kayaalp
Group - 13		Chairs: Shailesh V. Shrikhande (Mumbai, India), Robert Grützmann (Erlangen, Germany)	
496	PSUR-033	Postoperative day 3 serum-ascites albumin gradient may support early differentiation between biochemical leak and clinically relevant postoperative pancreatic fistula after partial pancreatic resection	Jan Bardenhagen
499	PSUR-034	Artificial intelligence for training and quality assessment in pancreatic surgery: current evidence and future directions	Jan Bardenhagen
503	PSUR-035	The triangle operation: 3D anatomical and histological characterisation of the vascular prism. Insights from a cadaveric study	Inês Faria Teixeira
515	PSUR-036	Glycaemic Burden After Total Pancreatectomy	Enis Salihi
529	PSUR-037	Biomechanical characterization of human pancreatic tissue through indentation: preliminary results for the development of artificial surgical phantom	Michele Pagnanelli
539	PSUR-038	Superior Mesenteric Vein/Portal Vein Resection for BR/LA Pancreatic Cancer Patients after Neoadjuvant Therapy	Jingcheng Zhang
710	PSUR-039	Inflammatory vs Non-Inflammatory Delayed Gastric Emptying After Pancreatoduodenectomy: A Distinct Clinical Phenotype Beyond ISGPS Classification	Alice Cattelani
548	PSUR-040	Impact of Chronic Corticosteroid Therapy on Postoperative Outcomes After Pancreatic Surgery: An International Multicenter Retrospective Study	Riccardo Pellegrini
558	PSUR-041	Pancreatic texture-specific thresholds for drain amylase and inflammatory markers to guide postoperative management after pancreatoduodenectomy	Enis Salihi
565	PSUR-042	Ampullectomy Case for Ampullary Adenoma	Muhammed Ali Özdemir
594	PSUR-043	MicRobiome Analysis in patients underGoing pancrEatico-duodenectomy for pancreatic cancer (MIRAGE Study)	Claudio Ricci
595	PSUR-044	When Survival Models Fail: An Interpretable Machine Learning Anomaly Detection Approach for High-Risk Phenotyping in Resected Solid Pseudopapillary Tumors	Claudio Ricci
597	PSUR-045	TachoSil® to Prevent Postpancreatectomy Hemorrhage After Distal Pancreatectomy: A Propensity-Weighted Pilot Study	Carlo Ingaldi
600	PSUR-046	Variability in the Management of Postoperative Pancreatic Exocrine Insufficiency and Pancreatic Enzyme Replacement Therapy: A European Survey	Giulia Gasparini

608	PSUR-047	Delayed Gastric Emptying after Robotic Pancreatoduodenectomy: a retrospective European multicenter analysis	Riccardo Pellegrini
Beşiktaş Poster Hall / 13.00 - 14.00			*Please kindly note that each presentation is allocated 4 minutes (3-minute presentation + 1-minute discussion)
AbsRef	Pub Number	Title	Presenter
Group - 8		Chairs: Timothy B. Gardner (Dartmouth, USA), Natalya Guibertis (Odesa, Ukraine)	
106	PAPC-001	Enhanced early prediction of acute pancreatitis severity using a SHAP-driven XGBoost model: advancing beyond conventional scoring systems	María Lourdes Ruiz Rebollo
117	PAPC-002	Retrospective analysis of body composition in patients with walled-off pancreatic necrosis at a tertiary centre: a single-centre experience	Lilla Horváth
126	PAPC-003	Clinical Outcomes of the Minimally Invasive "Step-up Approach" in Severe Acute Pancreatitis Management	Igor A. Kryvoruchko
127	PAPC-004	The role of syndecan-1 in predicting the course of acute pancreatitis: analysis of treatment of 84 patients	Igor A. Kryvoruchko
135	PAPC-005	Body composition as a marker of acute pancreatitis severity: a systematic review and meta-analysis	Nina Blazevic
145	PAPC-006	Is stress-induced pancreatitis possible?	Natalya Gubergrits
167	PAPC-007	SHASTA-5 rationale and design: randomized, double-blind, placebo-controlled study to evaluate plozasiran efficacy for reduction of pancreatitis risk	Peter Hegyi
168	PAPC-008	Different spectrum of microorganisms and clinical characteristics in infected necrotizing pancreatitis patients with and without "gas bubbles"	Yixuan Ding
188	PAPC-009	The great imitator: necrotizing acute pancreatitis, pancreatic tumor, or extrapulmonary tuberculosis?	Emese Fürst
211	PAPC-010	A systematic review of measurement of oxidative stress and clinical implications in acute pancreatitis	Shantata Kudchadkar
220	PAPC-011	Progression from acute to chronic pancreatitis in children: A systematic review and meta-analysis	Endre Botond Gagyí
221	PAPC-012	Effect of esmolol on organ function in predicted severe acute pancreatitis: a multicenter randomized clinical trial	Lu Ke
230	PAPC-013	Type 1 Autoimmune Pancreatitis with Normal Serum IgG4 Levels: a Milder Variant or a Distinct Entity?	Salvatore Crucillà
239	PAPC-014	Prediction of long-term post-necrotic pancreatic dysfunction in patients with acute necrotizing pancreatitis	Liudmyla V. Levchenko
241	PAPC-015	Correlation between Body Mass Index and Extrapancreatic Destruction in Acute Necrotizing Pancreatitis	Inna O. Kovalska
Group - 9		Chairs: Vinciane Rebours (Paris, France), İlgin Özden (Istanbul, Türkiye)	
242	PAPC-016	The role of primary drainage of the retroperitoneal space in the treatment of intra-abdominal hypertension in acute severe pancreatitis	Ivanna A. Shchyhel
246	PAPC-017	Anticoagulant Therapy in Acute Pancreatitis-related Splanchnic Venous Thrombosis - A Retrospective cohort study	Devarajulu Mariyappan
251	PAPC-018	Does Timing Matters? ERCP Performed During Acute Versus Post-Acute Pancreatitis: A 25-Year Real-World Comparative Study From Two High-Volume Centers	Theodoros A Voulgaris
259	PAPC-019	Short-term outcomes of Arterial Divestment in Pancreatic Cancer: A Systematic Review and Single Arm Meta-analysis of observational studies	Vivek Peddakota
280	PAPC-020	Development and validation of an interpretable machine learning model for early prediction of organ failure in acute pancreatitis patients: A multicenter cohort study	Di Wu

303	PAPC-021	A higher spontaneous resolution rate of biliary sludge compared with gallstones may trigger a lower cholecystectomy rate after acute biliary pancreatitis	Max Ole Hubert
327	PAPC-022	Pancreatic Volume Increase Following GLP-1 Receptor Agonist Therapy: A Real-World CT-Based Cohort Study	Yanna Cai
336	PAPC-023	Serial Serum and Urine Proteomic Profiling Identifies Novel Prognostic Biomarkers on Admission for Predicting Severe Acute Pancreatitis	Zihan Yang
348	PAPC-024	Necrotizing of Pancreatitis: Five-Year Clinical Experience and Surgical management Strategy at Vivamed Clinic Tbilisi Georgia	Zurab Zurab Chkhaidze
353	PAPC-025	Diagnostic pitfalls of lipase elevation in active IBD: distinguishing true pancreatitis from inflammatory hyperlipasemia	Motaz Ashkar
386	PAPC-026	Serum proteomics profiling identifies Celsr3a and CTSC as novel acute pancreatitis diagnostic biomarkers with superior diagnostic performance to lipase	Yonghao Chen
432	PAPC-027	Microbiology of infected walled-off pancreas necrosis - a single center retrospective study	Gábor Gieszinger
457	PAPC-028	Impact of drugs on the incidence of post-ERCP pancreatitis: the PEP-TALK study	Chiara Coluccio
464	PAPC-029	A study of long-term follow-up of patients with recurrent acute pancreatitis	Gauri Kumbhar
476	PAPC-030	Comparative efficacy of Chinese herbal injections with blood-activating and stasis-resolving effects for severe acute pancreatitis: a systematic review and network meta-analysis	Yongzi Wu
Group - 10		Chairs: Georg Beyer (Munich, Germany), Sara Nikolic (Maribor, Slovenia)	
491	PAPC-031	IgG4-Related Pancreatobiliary Disease: Clinical Spectrum and Outcomes from a Single-Center Experience	Oussama Trabelsi
500	PAPC-032	Outcome selection in randomised controlled trials of drugs for acute pancreatitis	Juan Lin
509	PAPC-033	Utility of routine microbiology sampling following Lumen apposing metal stent (LAMS) insertion for walled off necrosis (WON) in patients with Severe necrotising pancreatitis (SAP)	Joshua Michael Clements
512	PAPC-034	Delayed cholecystectomy and 90-day recurrence after a first episode of acute biliary pancreatitis	Yavuz Özden
513	PAPC-035	Clinical predictors of new-onset diabetes after a first episode of acute pancreatitis	Yavuz Özden
514	PAPC-036	Association of Body Composition with Etiology and Disease Course in Acute Pancreatitis: A Prospective Observational Cohort Study of 1,347 Patients	Olga Julia Zahariev
524	PAPC-037	Digital Bowel Sound Analysis for Early Severity Prediction in Acute Pancreatitis	Ziying Han
527	PAPC-038	Splanchnic and extra-splanchnic venous thrombosis in moderately severe and severe acute pancreatitis: Predictors and outcomes from a prospective study	Vivek Peddakota
537	PAPC-039	Safety and Efficacy of ERCP and Cholecystectomy in Pregnant Patients with Biliary Pancreatitis	Dorottya Tarjan
540	PAPC-040	Chronic cardiac diseases, acute heart failure and ECG abnormalities are associated with worse outcomes in AP - a multicentre registry-based cohort study	Veronika Lillik
542	PAPC-041	Early changes in renal function predict key clinical outcomes in acute pancreatitis: a multicentre registry-based study	Edina Tari
543	PAPC-042	Non-invasive Ventilation for Prevention of Intubation in Severe Acute Pancreatitis: A Systematic Review and Meta-analysis	Marcell Kovács
545	PAPC-043	Changes in Pancreatic Morphology and Endocrine Function After Acute Pancreatitis: Preliminary Results of the GOULASH Plus Longitudinal Study	Alexandra Mikó
563	PAPC-044	Nosocomial infection surveillance in a tertiary pancreatic center: a prospective cohort study	Zoltán Hajnádý
582	PAPC-046	Perioperative skeletal muscle loss and clinical severity in surgically treated patients with infected necrotizing pancreatitis	Viktoriia Teterina
Group - 14		Chairs: Giuseppe Vanella (Milan, Italy), Gürhan Sisman (Istanbul, Türkiye)	

85	PEND-001	Percutaneous endoscopic necrosectomy as a promising treatment method for difficult collections of walled-off pancreatic necrosis	Agata Chwarscianek
97	PEND-002	Improved EUS-FNB needle-tip design limits the number of needle passes and argues the added value of ROSE in patients with Pancreatic Ductal Adenocarcinoma	Mike J.P. de Jong
137	PEND-003	From Visualization to Intervention EUS in IgG4-Related Acute Pancreatic Disease	Sofia Ivina
146	PEND-004	Forward-Viewing Echoendoscope-Guided Interventional Therapy for Pancreatic Cystic Lesions	Sofia Ivina
147	PEND-005	Hybrid EUS Interventions in Pancreatic Pseudocysts A Prospective Cohort Study	Sofia Ivina
169	PEND-006	Integrating ERCP within UK Higher Surgical Training: A Structured, Curriculum-Embedded Model	Javed Latif
215	PEND-007	EUS-guided tissue acquisition with or without on-site evaluation: a single center experience from the Hungarian Institute of Pancreatic Diseases	Camille Turquier
217	PEND-008	A Rare Case: Isolated Pancreatic Metastasis of Renal Cell Carcinoma	Rauf Mehtiyev
219	PEND-009	Late Pancreatic Metastasis of Renal Cell Carcinoma	Rauf Mehtiyev
223	PEND-010	Gastric Outlet Obstruction as a Rare Clinical Manifestation of Disconnected Pancreatic Duct Syndrome: Success of a Step-Down Conservative Strategy	Livia Zornetta
228	PEND-011	The efficacy and safety of endoscopic ultrasound-guided pancreatic drainage for main pancreatic duct obstruction	Sung Hyun Cho
229	PEND-012	Diagnostic Accuracy of On-site Evaluation Techniques in Pancreatic Neoplasia Sampling: A Systematic Review and Meta-analysis	Zoltán Imre Bánfalvi
245	PEND-013	Retrospective analysis of EUS-guided elastography and Histopathological results in differentiating solid Pancreatic lesions at the Institute of Pancreatic Diseases, Semmelweis University	Devarajulu Mariyappan
252	PEND-014	Biliary stricture anatomical characteristics affects the development of post-ERCP pancreatitis	Theodoros A Voulgaris
256	PEND-015	Diagnostic utility of pancreatic and bile duct brushing for pancreatic cancer during ERCP: a systematic review and meta-analysis	Gergely Kollányi
Group - 15		Chairs: Lucía Guilabert Sanz (Elche, Spain), Dong-Wan Seo (Soeoul, South Korea)	
272	PEND-016	Igor Khomiak, Petro Ogorodnyk, Andrii Deinychenko, Nataliia Yermak, Ivan Lukecha	Igor Khomiak
287	PEND-017	Preliminary experience on the incidence and severity of post-ERCP pancreatitis in distal malignant biliary obstruction: a single tertiary-center analysis	Salvatore Crucillà
294	PEND-018	Endoscopic Treatment of Difficult Bile Duct Stones	Igor Khomiak
319	PEND-019	Influence of papilla morphology on ERCP cannulation strategies: an international survey	Edina Tari
343	PEND-020	Kimura disease of the pancreas mimicking a solid pancreatic neoplasm: Diagnosis by EUS-guided fine-needle aspiration	Charalampos Thanos
359	PEND-021	Outcomes of endoscopic biliary drainage in pancreatic head cancer: a single-center experience	Manel Yakoubi
360	PEND-022	Predictors of ERCP failure in pancreatic head cancer: experience of a Tunisian center	Manel Yakoubi
361	PEND-023	Predictors of post-ERCP complications in pancreatic head cancer: a monocentric tunisian cohort	Manel Yakoubi
437	PEND-024	Feasibility of a Modified Intraductal Fully Covered Self-Expandable Metal Stent in Unresectable Malignant Hilar Obstruction	Tae Hoon Lee
441	PEND-025	Systemic Triplet-Regimen Chemotherapy could be a Major Contributing Factor to Stent Dysfunction in Patients with Malignant Hilar Obstruction	Chang Il Kwon
442	PEND-026	Impact of Fatty Liver and Visceral Fat on Post-ERCP Pancreatitis in patients undergoing ERCP with standard prophylaxis	Krishna P Bharadwaj
467	PEND-027	Tiered Management of ERCP-Induced Pancreatic Duct Injuries	Hao Luo

475	PEND-028	Percutaneous endoscopic necrosectomy: integrating a new modality into a step-up treatment approach for infected necrotizing pancreatitis	Gabriel Alexander Salg
556	PEND-030	Clinical relevance of biliary sampling and the impact of stent biofilms: a retrospective analysis from a tertiary referral centre	Emese Rita Fürst
579	PEND-031	Odesa Criteria 2026 (OC26): A novel diagnostic algorithm for AIP using SPEP and EUS Doppler	Sofia Ivina